Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy

被引:114
作者
Smith, CJ
Sabin, CA
Youle, MS
Kinloch-de Loes, S
Lampe, FC
Madge, S
Cropley, I
Johnson, MA
Phillips, AN
机构
[1] UCL Royal Free & Univ Coll Med Sch, Dept Primary Care & Populat Sci, London NW3 2PF, England
[2] UCL Royal Free & Univ Coll Med Sch, Royal Free Ctr HIV Med, London NW3 2PF, England
[3] UCL Royal Free & Univ Coll Med Sch, Dept Immunol & Mol Pathol, London NW3 2PF, England
[4] UCL Royal Free Hosp, Dept Infect Dis, London NW3 2QG, England
[5] UCL Royal Free Hosp, Dept Thorac Med, London NW3 2QG, England
基金
英国医学研究理事会;
关键词
D O I
10.1086/425075
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Highly active antiretroviral therapy (HAART) results in an improvement in immunologic function. We sought to investigate the factors associated with increases in CD4 cell count among human immunodeficiency virus (HIV)-positive antiretroviral-naive patients starting HAART. Methods. Five hundred ninety-six subjects were followed for a median of 2.5 years (interquartile range, 1.0-4.0 years). Factors associated with changes in CD4 cell counts in the first 3 months of HAART and from 3 months onwards were analyzed. Results. After 6, 12, and 24 months of HAART, the median increases in CD4 cell counts were 114, 181, and 248 cells/mm(3), respectively; 84%, 84%, and 80% of subjects had a virus load of <400 copies/mL during the same periods. White ethnicity, higher pre-HAART virus load, and lower pre-HAART CD4 and CD8 cell counts were associated with greater increases in CD4 cell counts during the first 3 months of HAART. From 3 months onward, a greater cumulative proportion of time spent with virus load <400 copies/mL was associated with a more favorable change in CD4 cell count (an average increase of 5.2 cells/mm(3)/year [95% confidence interval [CI], 3.8-6.7 cells/mm(3)/year] for each extra 10% cumulative time spent with a virus load <400 copies/mL) (P < .0001). For every 100 cells/mm(3) higher in baseline CD4 cell count, the increase was 6 cells/mm(3)/year less (95% CI, 2-11 cells/mm(3)/year) (P = .02). Sex, risk group, age, and HAART regimen were not associated with increases in CD4 cell counts. Conclusions. These findings emphasize the importance of maintaining virological suppression and suggest other factors that influence long-term CD4 cell response.
引用
收藏
页码:1860 / 1868
页数:9
相关论文
共 42 条
[1]   Progressive human immunodeficiency virus-specific immune recovery with prolonged viral suppression [J].
Angel, JB ;
Parato, KG ;
Kumar, A ;
Kravcik, S ;
Badley, AD ;
Fex, C ;
Ashby, D ;
Sun, E ;
Cameron, DW .
JOURNAL OF INFECTIOUS DISEASES, 2001, 183 (04) :546-554
[2]  
Bisset LR, 2001, J ACQ IMMUN DEF SYND, V27, P266, DOI 10.1097/00126334-200107010-00008
[3]   Proliferative responses to human immunodeficiency virus type 1 (HIV-1) antigens in HIV-1-infected patients with immune reconstitution [J].
Blankson, JN ;
Gallant, JE ;
Siliciano, RF .
JOURNAL OF INFECTIOUS DISEASES, 2001, 183 (04) :657-661
[4]  
BRAITSTEIN P, 2003, ANTIVIR THER S, V8, pS235
[5]  
Casado JL, 1999, ANTIVIR THER, V4, P157
[6]   Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects [J].
Chung, RT ;
Evans, SR ;
Yang, YJ ;
Theodore, D ;
Valdez, H ;
Clark, R ;
Shikuma, C ;
Nevin, T ;
Sherman, KE .
AIDS, 2002, 16 (14) :1915-1923
[7]   Coinfection with hepatitis viruses and outcome of initial Antiretroviral regimens in previously naive HIV-Infected subjects [J].
De Luca, A ;
Bugarini, R ;
Lepri, AC ;
Puoti, M ;
Girardi, E ;
Antinori, A ;
Poggio, A ;
Pagano, G ;
Tositti, G ;
Cadeo, G ;
Macor, A ;
Toti, M ;
Monforte, AD .
ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (18) :2125-2132
[8]   HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy [J].
Deeks, SG ;
Hecht, FM ;
Swanson, M ;
Elbeik, T ;
Loftus, R ;
Cohen, PT ;
Grant, RM .
AIDS, 1999, 13 (06) :F35-F43
[9]   Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study [J].
Egger, M ;
Hirschel, B ;
Francioli, P ;
Sudre, P ;
Wirz, M ;
Flepp, M ;
Rickenbach, M ;
Malinverni, R ;
Vernazza, P ;
Battegay, M ;
Bernasconi, E ;
Burgisser, P ;
Erb, P ;
Fierz, W ;
Grob, P ;
Gruninger, U ;
Jeannerod, L ;
Ledergerber, B ;
Luthy, R ;
Matter, L ;
Opravil, M ;
Paccaud, F ;
Perrin, L ;
Pichler, W ;
Piffaretti, GC ;
Rutschmann, O ;
Zanetti, G .
BMJ-BRITISH MEDICAL JOURNAL, 1997, 315 (7117) :1194-1199
[10]   Factors affecting patient adherence to highly active antiretroviral therapy [J].
Escobar, I ;
Campo, M ;
Martín, J ;
Fernández-Shaw, C ;
Pulido, F ;
Rubio, R .
ANNALS OF PHARMACOTHERAPY, 2003, 37 (06) :775-781